---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010977"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:59:32.958178+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC

## Summary
- Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.
- Preclinical models: ENV105 (carotuximab) combined with osimertinib restored drug sensitivity via metabolic reprogramming.
- CEO states CD105 is a central resistance mechanism across prostate, breast, colon, and lung cancers.
- ENV105 currently in Phase 2 for castrate-resistant prostate cancer and Phase 1 for lung cancer.
- Global NSCLC treatment market projected to reach $45B by 2030; drug resistance remains a major challenge.

## SEC filing metadata
- accession: 0001493152-25-010977
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315225010977/0001493152-25-010977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315225010977/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010977
- JSON: https://secwatch.observer/filing/0001493152-25-010977.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.